#### Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

# **144: Filer Information**

Filer CIK0001584759Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationImage: Contact Information

Name Phone E-Mail Address

## **144: Issuer Information**

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

001-39247 6200 LOOKOUT ROAD BOULDER COLORADO 80301 720-647-8519 Heyman Richard A.

Enliven Therapeutics, Inc.

Director

### **144: Securities Information**

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market		Approximate Date of Sale	
Common	Jefferies LLC 520 Madison Ave, 4th Fl New York NY 10022	1956	24684.72	41000000	12/20/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# **144: Securities To Be Sold**

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is Date this Donor a Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
-----------------------	----------------------	---	---	-------------------------------------	-------------------------------------	--------------------	------------------------

Common	02/25/2020 Previous Purchase	Enliven	1956	02/25/2020 N/A
		Therapeutics,		
		Inc		

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Nothing to Report **V** 

### 144: Remarks and Signature

Remarks12/20/2023Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-107/17/2023ATTENTION:07/17/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature
Richard T Kuehnle

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)